

Shaun G Goodman

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1470050/shaun-g-goodman-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

429
papers

27,122
citations

77
h-index

157
g-index

469
ext. papers

32,499
ext. citations

7.3
avg, IF

6.34
L-index

#	Paper	IF	Citations
429	Predictors of hospital mortality in the global registry of acute coronary events. <i>Archives of Internal Medicine</i> , 2003 , 163, 2345-53		1414
428	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018 , 379, 2097-2107	59.2	1277
427	A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. <i>New England Journal of Medicine</i> , 1997 , 337, 447-52	59.2	1192
426	A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 291, 2727-33	27.4	1064
425	Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). <i>BMJ, The</i> , 2006 , 333, 1091	5.9	941
424	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2018 , 392, 1519-1529	40	771
423	Apixaban with antiplatelet therapy after acute coronary syndrome. <i>New England Journal of Medicine</i> , 2011 , 365, 699-708	59.2	765
422	Initial Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2020 , 382, 1395-1407	59.2	642
421	Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. <i>New England Journal of Medicine</i> , 2012 , 367, 1297-309	59.2	631
420	Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 1892-900	27.4	624
419	Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 292, 45-54	27.4	570
418	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019 , 380, 1509-1524	59.2	538
417	Intravenous platelet blockade with cangrelor during PCI. <i>New England Journal of Medicine</i> , 2009 , 361, 2330-41	59.2	480
416	Platelet inhibition with cangrelor in patients undergoing PCI. <i>New England Journal of Medicine</i> , 2009 , 361, 2318-29	59.2	454
415	Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). <i>Lancet, The</i> , 2002 , 359, 373-7	40	423
414	Prehospital ticagrelor in ST-segment elevation myocardial infarction. <i>New England Journal of Medicine</i> , 2014 , 371, 1016-27	59.2	409
413	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. <i>New England Journal of Medicine</i> , 2017 , 376, 1933-1942	59.2	406

412	Routine early angioplasty after fibrinolysis for acute myocardial infarction. <i>New England Journal of Medicine</i> , 2009 , 360, 2705-18	59.2	376
411	Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. <i>Circulation</i> , 2009 , 119, 2877-85	16.7	371
410	Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. <i>Chest</i> , 2004 , 126, 461-9	5.3	342
409	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. <i>American Heart Journal</i> , 2014 , 168, 682-9	4.9	303
408	Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). <i>American Journal of Cardiology</i> , 2002 , 89, 791-6	3	235
407	Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 292, 89-96	27.4	217
406	Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 303, 1841-7	27.4	213
405	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. <i>Circulation</i> , 2019 , 140, 1693-1702	16.7	205
404	Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. <i>European Heart Journal</i> , 2007 , 28, 1072-8	9.5	197
403	Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. <i>European Heart Journal</i> , 2008 , 29, 609-17	9.5	195
402	Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?. <i>Circulation</i> , 2007 , 116, 2793-801	16.7	182
401	Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. <i>Circulation</i> , 2003 , 107, 238-44	16.7	182
400	Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 1785-94	27.4	176
399	Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. <i>American Journal of Medicine</i> , 2004 , 117, 73-81	2.4	176
398	From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). <i>European Heart Journal</i> , 2003 , 24, 1414-24	9.5	173
397	Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2061-2069	15.1	172
396	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update. <i>Circulation</i> , 2018 , 138, 527-536	16.7	164
395	Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. <i>New England Journal of Medicine</i> , 2017 , 376, 2032-2042	59.2	156

394	Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. <i>American Heart Journal</i> , 2003 , 146, 33-41	4.9	154
393	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 133-144	15.1	147
392	The expanded Global Registry of Acute Coronary Events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. <i>American Heart Journal</i> , 2009 , 158, 193-201.e1-5	4.9	145
391	Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. <i>European Heart Journal</i> , 2007 , 28, 2077-86	9.5	143
390	Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. <i>Circulation</i> , 2012 , 125, 978-86	16.7	139
389	Bridging the gender gap: Insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients with acute coronary syndromes. <i>American Heart Journal</i> , 2012 , 163, 66-73	4.9	138
388	Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events [GRACE]). <i>American Journal of Cardiology</i> , 2004 , 93, 288-93	3	138
387	Factors influencing underutilization of evidence-based therapies in women. <i>European Heart Journal</i> , 2011 , 32, 1337-44	9.5	134
386	Contemporary management of dyslipidemia in high-risk patients: targets still not met. <i>American Journal of Medicine</i> , 2006 , 119, 676-83	2.4	133
385	Safety and tolerability of atropaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin in the Acute Coronary Syndromes Trial. <i>Circulation</i> , 2011 , 123, 1843-53	16.7	130
384	Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 693-8	15.1	130
383	Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. <i>European Heart Journal</i> , 2010 , 31, 2156-69	9.5	129
382	Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. <i>European Heart Journal</i> , 2014 , 35, 1873-80	9.5	126
381	Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. <i>American Heart Journal</i> , 2007 , 154, 1108-15	4.9	126
380	Validation of the Global Registry of Acute Coronary Event (GRACE) risk score for in-hospital mortality in patients with acute coronary syndrome in Canada. <i>American Heart Journal</i> , 2009 , 158, 392-9	4.9	123
379	Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , 2008 , 133, 670S-707S	5.3	123
378	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 618-628	18.1	120
377	Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 61-71	15.1	119

376	Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes. <i>Archives of Internal Medicine</i> , 2007 , 167, 1009-16		118
375	Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 761-771	27.4	107
374	Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. <i>Circulation</i> , 2013 , 128, 823-33	16.7	103
373	Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?. <i>European Heart Journal</i> , 2007 , 28, 1717-22	9.5	103
372	Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. <i>European Heart Journal</i> , 2009 , 30, 321-9	9.5	99
371	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 387-396	15.1	96
370	In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratified by the GRACE risk score. <i>American Journal of Cardiology</i> , 2005 , 96, 913-6	3	95
369	Unprotected left main revascularization in patients with acute coronary syndromes. <i>European Heart Journal</i> , 2009 , 30, 2308-17	9.5	92
368	Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. <i>American Heart Journal</i> , 2005 , 150, 690-4	4.9	91
367	G-protein-coupled receptors as signaling targets for antiplatelet therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009 , 29, 449-57	9.4	90
366	Does simplicity compromise accuracy in ACS risk prediction? A retrospective analysis of the TIMI and GRACE risk scores. <i>PLoS ONE</i> , 2009 , 4, e7947	3.7	90
365	Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 38-43	15.1	89
364	Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , 2008 , 133, 708S-775S	5.3	88
363	Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. <i>Catheterization and Cardiovascular Interventions</i> , 2007 , 69, 73-83	2.7	88
362	The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2006 , 151, 654-60	4.9	88
361	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1167-1176	15.1	87
360	Time to treatment influences the impact of ST-segment resolution on one-year prognosis: insights from the assessment of the safety and efficacy of a new thrombolytic (ASSENT-2) trial. <i>Circulation</i> , 2001 , 104, 2653-9	16.7	86
359	Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. <i>American Journal of Cardiology</i> , 1998 , 82, 19L-24L	3	85

358	Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2003 , 146, 999-1006	4.9	83
357	One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary Syndromes Registry). <i>American Journal of Cardiology</i> , 2004 , 94, 25-9	3	82
356	Cardiogenic shock complicating acute coronary syndromes: insights from the Global Registry of Acute Coronary Events. <i>American Heart Journal</i> , 2012 , 163, 963-71	4.9	81
355	Age-related differences in the management and outcome of patients with acute coronary syndromes. <i>American Heart Journal</i> , 2006 , 151, 352-9	4.9	79
354	Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. <i>Canadian Journal of Cardiology</i> , 2010 , 26, 297-302	3.8	77
353	Elevated leukocyte count and adverse hospital events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2004 , 147, 42-8	4.9	77
352	Clinical trials evaluating red blood cell transfusion thresholds: An updated systematic review and with additional focus on patients with cardiovascular disease. <i>American Heart Journal</i> , 2018 , 200, 96-101	4.9	74
351	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9,	6	73
350	Clinical trial–derived risk model may not generalize to real-world patients with acute coronary syndrome. <i>American Heart Journal</i> , 2004 , 148, 1020-7	4.9	73
349	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. <i>Circulation</i> , 2019 , 140, 103-112	16.7	72
348	Relationship of ST elevation in lead aVR with angiographic findings and outcome in non-ST elevation acute coronary syndromes. <i>American Heart Journal</i> , 2007 , 154, 71-8	4.9	71
347	Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): the first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction. <i>American Heart Journal</i> , 2010 , 159, 354-60	4.9	70
346	A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 1346-54	15.1	69
345	Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. <i>European Heart Journal</i> , 2014 , 35, 233-41	9.5	67
344	Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2019 , 4, 273-286	16.2	65
343	Association of Clinical Factors and Therapeutic Strategies With Improvements in Survival Following Non-ST-Elevation Myocardial Infarction, 2003-2013. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 1073-82	27.4	65
342	Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. <i>European Heart Journal</i> , 2014 , 35, 2516-23	9.5	65
341	Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. <i>European Heart Journal</i> , 2009 , 30, 549-57	9.5	65

340	Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators. <i>Circulation</i> , 1998 , <i>97</i> , 444-50	16.7	63
339	Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non-Q wave myocardial infarction. (LATE Study Investigators). <i>Journal of the American College of Cardiology</i> , 1996 , <i>27</i> , 1327-32	15.1	62
338	Clopidogrel Pharmacogenetics. <i>Circulation: Cardiovascular Interventions</i> , 2019 , <i>12</i> , e007811	6	60
337	Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. <i>Lancet Diabetes and Endocrinology</i> , 2020 , <i>8</i> , 418-435	18.1	59
336	In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , <i>4</i> , 499-508	4.3	59
335	Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. <i>American Journal of Medicine</i> , 2015 , <i>128</i> , 766-75	2.4	58
334	An open-Label, 2 X 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. <i>American Heart Journal</i> , 2018 , <i>200</i> , 17-23	4.9	56
333	Influence of age on use of cardiac catheterization and associated outcomes in patients with non-ST-elevation acute coronary syndromes. <i>American Journal of Cardiology</i> , 2009 , <i>103</i> , 1530-6	3	56
332	Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events. <i>European Heart Journal</i> , 2010 , <i>31</i> , 667-75	9.5	53
331	Applying the evidence: do patients with stroke, coronary artery disease, or both achieve similar treatment goals?. <i>Stroke</i> , 2009 , <i>40</i> , 1417-24	6.7	53
330	Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. <i>Circulation</i> , 2020 , <i>141</i> , 1608-1617	16.7	52
329	Optimal medical therapy for non-ST-segment-elevation acute coronary syndromes: exploring why physicians do not prescribe evidence-based treatment and why patients discontinue medications after discharge. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010 , <i>3</i> , 530-7	5.8	52
328	Spontaneous reperfusion in ST-elevation myocardial infarction: comparison of angiographic and electrocardiographic assessments. <i>American Heart Journal</i> , 2008 , <i>156</i> , 248-55	4.9	52
327	Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008 , <i>5</i> , 580-9		51
326	High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. <i>JAMA - Journal of the American Medical Association</i> , 2005 , <i>294</i> , 2594-600	27.4	50
325	Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?. <i>American Heart Journal</i> , 2000 , <i>139</i> , 423-9	4.9	50
324	Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy. <i>Journal of the American College of Cardiology</i> , 2000 , <i>36</i> , 1507-13	15.1	50
323	Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2018 , <i>3</i> , 391-399	16.2	49

322	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. <i>Circulation</i> , 2020 , 141, 1618-1627	16.7	48
321	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. <i>Circulation</i> , 2020 , 141, 781-783	16.7	48
320	The 12-lead electrocardiogram as a predictive tool of mortality after acute myocardial infarction: current status in an era of revascularization and reperfusion. <i>American Heart Journal</i> , 2006 , 152, 11-8	4.9	47
319	Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. <i>European Heart Journal</i> , 2020 , 41, 86-94	9.5	45
318	Cost-effectiveness of specialized multidisciplinary heart failure clinics in Ontario, Canada. <i>Value in Health</i> , 2010 , 13, 915-21	3.3	44
317	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2020 , 41, 4245-4255	9.5	44
316	High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events. <i>European Heart Journal</i> , 2015 , 36, 976-83	9.5	42
315	Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007. <i>American Journal of Cardiology</i> , 2011 , 108, 617-24	3	42
314	Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarction. <i>European Heart Journal</i> , 2018 , 39, 3798-3806	9.5	42
313	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. <i>Circulation</i> , 2019 , 140, 2054-2062	16.7	41
312	Canada Acute Coronary Syndrome Risk Score: a new risk score for early prognostication in acute coronary syndromes. <i>American Heart Journal</i> , 2013 , 166, 58-63	4.9	41
311	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. <i>Circulation</i> , 2019 , 140, 1921-1932	16.7	40
310	Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). <i>Canadian Journal of Cardiology</i> , 2010 , 26, e330-5	3.8	40
309	Unraveling the spectrum of left bundle branch block in acute myocardial infarction: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials. <i>American Heart Journal</i> , 2006 , 151, 10-5	4.9	40
308	Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial infarction to open the Coronary artery (ATLANTIC) study. <i>American Heart Journal</i> , 2010 , 151, 10-5	4.9	39
307	Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective. <i>European Heart Journal</i> , 2010 , 31, 1328-36	9.5	39
306	Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators. <i>Journal of the American College of Cardiology</i> , 1997 , 29, 770-7	15.1	37
305	Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial. <i>Journal of General Internal Medicine</i> , 2008 , 23, 310-6	4	37

304	Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. <i>Circulation</i> , 2007 , 116, 2669-77	16.7	37
303	Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes. <i>American Heart Journal</i> , 2006 , 152, 676-83	4.9	37
302	Secular trends in acute coronary syndrome hospitalization from 1994 to 2005. <i>Canadian Journal of Cardiology</i> , 2010 , 26, 129-34	3.8	36
301	Outcomes of Women and Men With Acute Coronary Syndrome Treated With and Without Percutaneous Coronary Revascularization. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	35
300	Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2819-2828	15.1	34
299	Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. <i>European Heart Journal</i> , 2011 , 32, 2256-65	9.5	34
298	Rationale and design of the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). <i>American Heart Journal</i> , 2008 , 155, 19-25	4.9	34
297	Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 119-127	15.1	33
296	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1177-1186	15.1	33
295	Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. <i>International Journal of Cardiology</i> , 2010 , 139, 123-33	3.2	32
294	Treatment and one-year outcome of patients with renal dysfunction across the broad spectrum of acute coronary syndromes. <i>Canadian Journal of Cardiology</i> , 2006 , 22, 115-20	3.8	32
293	Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 777-787	15.1	31
292	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. <i>Diabetes Care</i> , 2020 , 43, 446-452	14.6	31
291	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. <i>Circulation</i> , 2021 , 143, 583-596	16.7	31
290	Paradoxical use of invasive cardiac procedures for patients with non-ST segment elevation myocardial infarction: an international perspective from the CRUSADE Initiative and the Canadian ACS Registries I and II. <i>Canadian Journal of Cardiology</i> , 2007 , 23, 1073-9	3.8	30
289	Temporal trends in the use of invasive cardiac procedures for non-ST segment elevation acute coronary syndromes according to initial risk stratification. <i>Canadian Journal of Cardiology</i> , 2009 , 25, e370-6	3.8	29
288	Relation between obesity and the attainment of optimal blood pressure and lipid targets in high vascular risk outpatients. <i>American Journal of Cardiology</i> , 2010 , 106, 1270-6	3	29
287	Comparison of baseline characteristics, management and outcome of patients with non-ST-segment elevation acute coronary syndrome in versus not in clinical trials. <i>American Journal of Cardiology</i> , 2010 , 106, 1389-96	3	29

286	Relation between hemoglobin level and recurrent myocardial ischemia in acute coronary syndromes detected by continuous electrocardiographic monitoring. <i>American Journal of Cardiology</i> , 2010 , 106, 1417-22	3	29
285	Prognostic significance of admission heart failure in patients with non-ST-elevation acute coronary syndromes (from the Canadian Acute Coronary Syndrome Registries). <i>American Journal of Cardiology</i> , 2006 , 98, 470-3	3	29
284	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. <i>European Heart Journal</i> , 2020 , 41, 2248-2258	9.5	29
283	Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y ₁ Inhibitor Therapy: A Meta-Analysis. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 739-750	5	29
282	Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. <i>European Heart Journal</i> , 2015 , 36, 385-92a	9.5	28
281	Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatid. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. <i>American Heart Journal</i> , 2011 , 142, 100-107	4.9	28
280	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2019 , 40, 2801-2809	9.5	27
279	Relationship between time to invasive assessment and clinical outcomes of patients undergoing an early invasive strategy after fibrinolysis for ST-segment elevation myocardial infarction: a patient-level analysis of the randomized early routine invasive clinical trials. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 166-174	5	27
278	Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes. <i>American Heart Journal</i> , 2009 , 157, 642-50.e1	4.9	27
277	Comparison of primary coronary angioplasty versus thrombolysis in patients with ST-segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram. <i>American Journal of Cardiology</i> , 2001 , 88, 842-7	3	27
276	Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI. <i>American Heart Journal</i> , 2017 , 192, 105-112	4.9	26
275	Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: insights from the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI).	9.5	26
274	Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies. <i>Circulation</i> , 2001 , 103, 954-60	16.7	26
273	Frailty and Outcomes After Myocardial Infarction: Insights From the CONCORDANCE Registry. <i>Journal of the American Heart Association</i> , 2018 , 7, e009859	6	26
272	Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H ₁ Analysis. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 646-56	5	25
271	Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy. <i>European Heart Journal</i> , 2008 , 29, 871-9	9.5	25
270	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. <i>Circulation</i> , 2019 , 140, 1578-1589	16.7	24
269	Missed opportunities for the secondary prevention of cardiovascular disease in Canada. <i>Canadian Journal of Cardiology</i> , 2007 , 23, 1124-30	3.8	24

268	Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy. <i>American Heart Journal</i> , 2000 , 139, 962-70	4.9	24
267	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2297-2308	15.1	23
266	Temporal Trends of Women Enrollment in Major Cardiovascular Randomized Clinical Trials. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 653-660	3.8	23
265	High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. <i>American Heart Journal</i> , 2018 , 202, 97-103	4.9	23
264	Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. <i>American Heart Journal</i> , 2015 , 170, 683-694.e3	4.9	22
263	Management patterns of non-ST segment elevation acute coronary syndromes in relation to prior coronary revascularization. <i>American Heart Journal</i> , 2010 , 159, 40-6	4.9	22
262	Temporal trend of in-hospital major bleeding among patients with non ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2010 , 160, 420-7	4.9	22
261	Disparities in management patterns and outcomes of patients with non-ST-elevation acute coronary syndrome with and without a history of cerebrovascular disease. <i>American Journal of Cardiology</i> , 2010 , 105, 1083-9	3	22
260	Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries. <i>American Journal of Cardiology</i> , 1998 , 81, 1078-84	3	22
259	Discordance between physicians' estimation of patient cardiovascular risk and use of evidence-based medical therapy. <i>American Journal of Cardiology</i> , 2008 , 102, 1142-5	3	22
258	Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein >or=100 mg/dl versus. <i>American Journal of Cardiology</i> , 2007 , 100, 913-8	3	22
257	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 39-49	27.4	22
256	Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. <i>American Heart Journal</i> , 2017 , 190, 135-139	4.9	21
255	Cardiovascular Risk Factors and In-hospital Mortality in Acute Coronary Syndromes: Insights From the Canadian Global Registry of Acute Coronary Events. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 1455-61	3.8	21
254	Do clinical factors explain persistent sex disparities in the use of acute reperfusion therapy in STEMI in Sweden and Canada?. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013 , 2, 350-8	4.3	21
253	Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint. <i>European Heart Journal</i> , 2013 , 34, 903-8	9.5	21
252	Management of risk in peripheral artery disease: recent therapeutic advances. <i>American Heart Journal</i> , 2005 , 150, 35-40	4.9	21
251	Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020 , 159, 2302-2309.e6	1.5	21

250	Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial. <i>American Heart Journal</i> , 2016 , 182, 62-71	4.9	20
249	Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian acute coronary syndrome reflective. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 1725-31	3.8	20
248	Targeted temperature management processes and outcomes after out-of-hospital cardiac arrest: an observational cohort study*. <i>Critical Care Medicine</i> , 2014 , 42, 2565-74	1.4	20
247	Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. <i>International Journal of Cardiology</i> , 2010 , 144, 36-41	3.2	20
246	Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the Global Registry of Acute Coronary Events. <i>American Heart Journal</i> , 2010 , 160, 855-61	4.9	20
245	ST-segment depression in non-ST elevation acute coronary syndromes: quantitative analysis may not provide incremental prognostic value beyond comprehensive risk stratification. <i>American Heart Journal</i> , 2006 , 152, 270-6	4.9	20
244	Development and prognosis of non-Q-wave myocardial infarction in the thrombolytic era. <i>American Heart Journal</i> , 2002 , 144, 243-250	4.9	20
243	Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term risk, clinical manaGement and healthcare Resource utilization of stable coronary artery diSease (TIGRIS) observational study. <i>International Journal of Cardiology</i> , 2017 , 236, 54-60	3.2	19
242	Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 366-377	3.8	19
241	Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an EXTRACT-TIMI 25 analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2009 , 27, 11-7	5.1	19
240	Long-term prognostic value and therapeutic implications of continuous ST-segment monitoring in acute coronary syndrome. <i>American Heart Journal</i> , 2007 , 153, 500-6	4.9	19
239	ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. <i>European Heart Journal</i> , 2003 , 24, 1515-22	9.5	19
238	Negative T waves shortly after ST-elevation acute myocardial infarction are a powerful marker for improved survival rate. <i>American Heart Journal</i> , 2000 , 140, 385-94	4.9	19
237	A cluster randomized trial of objective risk assessment versus standard care for acute coronary syndromes: Rationale and design of the Australian GRACE Risk score Intervention Study (AGRIS). <i>American Heart Journal</i> , 2015 , 170, 995-1004.e1	4.9	18
236	Treatment and outcomes of patients with suspected acute coronary syndromes in relation to initial diagnostic impressions (insights from the Canadian Global Registry of Acute Coronary Events [GRACE] and Canadian Registry of Acute Coronary Events [CANRACE]). <i>American Journal of Cardiology</i> , 2013 , 111, 202-7	3	18
235	Use and timing of coronary angiography and associated in-hospital outcomes in Canadian non-ST-segment elevation myocardial infarction patients: insights from the Canadian Global Registry of Acute Coronary Events. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 1429-35	3.8	18
234	Prognostic significance of presenting blood pressure in non-ST-segment elevation acute coronary syndrome in relation to prior history of hypertension. <i>American Heart Journal</i> , 2013 , 166, 716-22	4.9	18
233	Management and outcome of acute coronary syndrome patients in relation to prior history of atrial fibrillation. <i>Canadian Journal of Cardiology</i> , 2012 , 28, 443-9	3.8	18

232	Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2007 , 153, 960-9	4.9	18
231	Troponin is more useful than creatine kinase in predicting one-year mortality among acute coronary syndrome patients. <i>European Heart Journal</i> , 2004 , 25, 2006-12	9.5	18
230	Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. <i>American Journal of Cardiology</i> , 1994 , 74, 657-61	3	18
229	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 162-171	15.1	17
228	Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy Adenosine (AMISTAD) trial. <i>American Heart Journal</i> , 2005 , 150, 659-65	4.9	17
227	Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy. <i>American Heart Journal</i> , 2016 , 180, 82-9	4.9	17
226	QRS prolongation in patients with acute coronary syndromes. <i>American Heart Journal</i> , 2010 , 159, 593-8	4.9	16
225	Bleeding and outcome in acute coronary syndrome: insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial. <i>American Heart Journal</i> , 2008 , 156, 769-75	4.9	16
224	Differences between local hospital and core laboratory interpretation of the admission electrocardiogram in patients with acute coronary syndromes and their relation to outcome. <i>American Journal of Cardiology</i> , 2007 , 100, 169-74	3	16
223	How does the prognosis of diabetes compare with that of established vascular disease? Insights from the Canadian Vascular Protection (VP) Registry. <i>American Heart Journal</i> , 2004 , 148, 1028-33	4.9	16
222	Prognostic value of dipyridamole SPECT imaging in low-risk patients after myocardial infarction. <i>Journal of Nuclear Cardiology</i> , 2001 , 8, 136-43	2.1	16
221	Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial. <i>American Heart Journal</i> , 2002 , 144, 60-7	4.9	16
220	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. <i>Circulation</i> , 2021 , 143, 1109-1122	16.7	16
219	Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (COAPT). <i>American Heart Journal</i> , 2021 , 181, 212-21	4.9	16
218	Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. <i>American Heart Journal</i> , 2021 , 231, 121-127	4.9	16
217	Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design. <i>JACC: CardioOncology</i> , 2020 , 2, 70-81	3.8	15
216	Identification and management of patients at elevated cardiometabolic risk in canadian primary care: how well are we doing?. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 960-8	3.8	15
215	Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experience. <i>American Heart Journal</i> , 2009 , 158, 917-24	4.9	15

214	Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial. <i>American Heart Journal</i> , 2005 , 149, 275-83	4.9	15
213	Supporting a call to action for peripheral artery disease: insights from two prospective clinical registries. <i>Journal of Vascular Surgery</i> , 2006 , 44, 776-81	3.5	15
212	Skin tissue cholesterol (SkinTc) is related to angiographically-defined cardiovascular disease. <i>Atherosclerosis</i> , 2003 , 171, 255-8	3.1	15
211	Is There a Sex Gap in Surviving an Acute Coronary Syndrome or Subsequent Development of Heart Failure?. <i>Circulation</i> , 2020 , 142, 2231-2239	16.7	15
210	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e008018	6	15
209	Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. <i>American Journal of Cardiovascular Drugs</i> , 2019 , 19, 173-183	4	15
208	Association of Anemia With Outcomes Among ST-Segment-Elevation Myocardial Infarction Patients Receiving Primary Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e007175	6	15
207	The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. <i>American Heart Journal</i> , 2015 , 169, 743-50	4.9	14
206	Reperfusion strategies and outcomes of ST-segment elevation myocardial infarction patients in Canada: observations from the Global Registry of Acute Coronary Events (GRACE) and the Canadian Registry of Acute Coronary Events (CANRACE). <i>Canadian Journal of Cardiology</i> , 2012 , 28, 40-7	3.8	14
205	Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 34, 36-43	5.1	14
204	Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification. <i>American Heart Journal</i> , 2007 , 153, 493-9	4.9	14
203	Transfer for urgent percutaneous coronary intervention early after thrombolysis for ST-elevation myocardial infarction: the TRANSFER-AMI pilot feasibility study. <i>Canadian Journal of Cardiology</i> , 2006 , 22, 1121-6	3.8	14
202	Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1289-97	15.1	13
201	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e005858	5.8	13
200	Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non-ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , 2013 , 166, 290-7	4.9	13
199	Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit). <i>American Journal of Cardiology</i> , 2015 , 115, 641-6	3	13
198	Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome. <i>American Heart Journal</i> , 2014 , 168, 189-96.e1	4.9	13
197	Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade. <i>Catheterization and Cardiovascular Interventions</i> , 2005 , 66, 149-57	2.7	13

196	Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial. <i>EuroIntervention</i> , 2017 , 13, 69-77	3.1	13
195	Temporal Trends in Utilization of Cardiac Therapies and Outcomes for Myocardial Infarction by Degree of Chronic Kidney Disease: A Report From the NCDR Chest Pain-MI Registry. <i>Journal of the American Heart Association</i> , 2018 , 7, e010394	6	13
194	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. <i>Circulation</i> , 2021 , 144, 1295-1307	16.7	13
193	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 421-433	15.1	13
192	Association between gender and short-term outcome in patients with ST elevation myocardial infarction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis. <i>BMJ Open</i> 2017 , 7, e015241	3	12
191	Effectiveness of Interventions Aimed at Increasing Statin-Prescribing Rates in Primary Cardiovascular Disease Prevention: A Systematic Review of Randomized Clinical Trials. <i>JAMA Cardiology</i> , 2019 , 4, 1160-1169	16.2	12
190	Prognostic significance of low QRS voltage on the admission electrocardiogram in acute coronary syndromes. <i>International Journal of Cardiology</i> , 2015 , 190, 34-9	3.2	12
189	Clinical Characteristics, Management, and Outcomes of Acute Coronary Syndrome in Patients With Right Bundle Branch Block on Presentation. <i>American Journal of Cardiology</i> , 2016 , 117, 754-9	3	12
188	Alignment of site versus adjudication committee-based diagnosis with patient outcomes: Insights from the Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 trial. <i>Clinical Trials</i> , 2016 , 13, 140-8	2.2	12
187	Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative. <i>Journal of Thrombosis and Thrombolysis</i> , 2006 , 21, 211-20	5.1	12
186	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. <i>European Heart Journal</i> , 2020 , 41, 4114-4123	9.5	12
185	Evaluation of the impact of the GRACE risk score on the management and outcome of patients hospitalised with non-ST elevation acute coronary syndrome in the UK: protocol of the UKGRIS cluster-randomised registry-based trial. <i>BMJ Open</i> , 2019 , 9, e032165	3	12
184	Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial. <i>Journal of the American Heart Association</i> , 2018 , 7, e009304	6	12
183	The underutilisation of dual antiplatelet therapy in acute coronary syndrome. <i>International Journal of Cardiology</i> , 2017 , 240, 30-36	3.2	11
182	The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 336-43	3.8	11
181	Recurrent ischemia across the spectrum of acute coronary syndromes: prevalence and prognostic significance of (re-)infarction and ST-segment changes in a large contemporary registry. <i>International Journal of Cardiology</i> , 2010 , 145, 15-20	3.2	11
180	Usefulness of quantitative versus qualitative ST-segment depression for risk stratification of non-ST elevation acute coronary syndromes in contemporary clinical practice. <i>American Journal of Cardiology</i> , 2008 , 101, 919-24	3	11
179	Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial. <i>European Heart Journal</i> , 2007 , 28, 1079-84	9.5	11

178	Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes: A Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 304-313	16.2	11
177	Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 208-217	4.3	11
176	Interprovincial Differences in Canadian Coronary Care Unit Resource Use and Outcomes. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 166-169	3.8	10
175	Living alone and cardiovascular disease outcomes. <i>Heart</i> , 2019 , 105, 1087-1095	5.1	10
174	Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. <i>Heart</i> , 2015 , 101, 1475-84	5.1	10
173	Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. <i>American Heart Journal</i> , 2018 , 202, 89-96	4.9	10
172	GRACE risk score: Sex-based validity of in-hospital mortality prediction in Canadian patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2017 , 244, 24-29	3.2	10
171	Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada. <i>ClinicoEconomics and Outcomes Research</i> , 2014 , 6, 49-62	1.7	10
170	Achieving quality indicator benchmarks and potential impact on coronary heart disease mortality. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 756-62	3.8	10
169	A dynamic model forecasting myocardial infarct size before, during, and after reperfusion therapy: an ASSENT-2 ECG/VCG substudy. <i>European Heart Journal</i> , 2005 , 26, 1726-33	9.5	10
168	Prognostic value of dynamic electrocardiographic T wave changes in non-ST elevation acute coronary syndrome. <i>Heart</i> , 2016 , 102, 1396-402	5.1	10
167	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, 33-43	3.9	10
166	In-hospital management and outcomes of acute coronary syndromes in relation to prior history of heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016 , 5, 214-22	4.3	9
165	Comparison of the efficacy of pharmacoinvasive management for ST-segment elevation myocardial infarction in smokers versus non-smokers (from the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction). <i>American Journal of Cardiology</i> , 2014 , 114, 955-61	3	9
164	Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian Observational AntiPlatelet sTudy. <i>International Journal of Cardiology</i> , 2017 , 228, 459-464	3.2	9
163	Temporal patterns of lipid testing and statin therapy in acute coronary syndrome patients (from the Canadian GRACE Experience). <i>American Journal of Cardiology</i> , 2012 , 109, 1418-24	3	9
162	Use of clopidogrel post-coronary artery bypass surgery in canadian patients with acute coronary syndromes. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 711-5	3.8	9
161	Evaluation of left ventricular ejection fraction in non-ST-segment elevation acute coronary syndromes and its relationship to treatment. <i>American Heart Journal</i> , 2010 , 159, 605-11	4.9	9

160	Predictors and implications of Q-waves in ST-elevation acute coronary syndromes. <i>American Journal of Medicine</i> , 2009 , 122, 144-51	2.4	9
159	Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients. <i>Canadian Journal of Cardiology</i> , 2006 , 22, 835-9	3.8	9
158	Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm. <i>Canadian Journal of Cardiology</i> , 2006 , 22, 663-77	3.8	9
157	The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2. <i>European Heart Journal</i> , 2003 , 24, 1024-34	9.5	9
156	Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy. <i>American Heart Journal</i> , 2003 , 146, 640-5	4.9	9
155	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , 2021 , 44, 1219-1227	14.6	9
154	Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2017 , 63, 1214-1226	5.5	8
153	Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. <i>Canadian Journal of Diabetes</i> , 2018 , 42, 130-137	2.1	8
152	Temporal trends and referral factors for cardiac rehabilitation post-acute coronary syndrome in ontario: insights from the Canadian Global Registry of Acute Coronary Events. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 1604-9	3.8	8
151	Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , 2010 , 31, 958-66	9.5	8
150	Ischemic stroke: a cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. <i>Canadian Journal of Cardiology</i> , 2008 , 24, 705-8	3.8	8
149	Local hospital vs. core-laboratory interpretation of the admission electrocardiogram in acute coronary syndromes: increased mortality in patients with unrecognized ST-elevation myocardial infarction. <i>European Heart Journal</i> , 2008 , 29, 31-7	9.5	8
148	The prognostic value of the admission and predischage electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience. <i>American Heart Journal</i> , 2006 , 152, 277-84	4.9	8
147	Treatment of silent ischemia in unstable angina: a randomized comparison of sustained-release verapamil versus metoprolol. <i>Clinical Cardiology</i> , 1995 , 18, 653-8	3.3	8
146	Does ambulatory monitoring contribute to exercise testing and myocardial perfusion scintigraphy in the prediction of the extent of coronary artery disease in stable angina?. <i>American Journal of Cardiology</i> , 1994 , 73, 747-52	3	8
145	Consistency of benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis. <i>Heart</i> , 2015 , 101, 1554-61	5.1	7
144	Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. <i>International Journal of Cardiology</i> , 2018 , 257, 78-83	3.2	7
143	Use of clinical risk stratification in non-ST elevation acute coronary syndromes: an analysis from the CONCORDANCE registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2018 , 4, 309-317	4.6	7

142	Rationale and design of the long-Term risk, clinical manaGement, and healthcare Resource utilization of stable coronary artery diSease in post-myocardial infarction patients (TIGRIS) study. <i>Clinical Cardiology</i> , 2017 , 40, 1197-1204	3.3	7
141	The association between prior use of aspirin and/or warfarin and the in-hospital management and outcomes in patients presenting with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). <i>Canadian Journal of Cardiology</i> , 2012 , 28, 48-53	3.8	7
140	Patient age, ethnicity, medical history, and risk factor profile, but not drug insurance coverage, predict successful attainment of glycemic targets: Time 2 Do More Quality Enhancement Research Initiative (T2DM QUERI). <i>Diabetes Care</i> , 2010 , 33, 2558-60	14.6	7
139	Quantitative troponin elevation does not provide incremental prognostic value beyond comprehensive risk stratification in patients with non-ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , 2008 , 155, 718-24	4.9	7
138	Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library. <i>American Heart Journal</i> , 2004 , 148, 269-76	4.9	7
137	Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 65-74	7	7
136	Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations. <i>Canadian Journal of Cardiology</i> , 2016 , 32, S15-34	3.8	7
135	Rationale and design of the TAILOR-PCI digital study: Transitioning a randomized controlled trial to a digital registry. <i>American Heart Journal</i> , 2021 , 232, 84-93	4.9	7
134	Meta-Analysis of Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin According to Time in Therapeutic Range in Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021 , 140, 62-68	3	7
133	Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events). <i>American Journal of Cardiology</i> , 2018 , 122, 944-951 ³		7
132	Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation: From the Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation (FREEDOM AF) and Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation (CONNECT AF). <i>American Journal of Cardiology</i> , 2017 , 119, 100-107	3	6
131	Population-Based Study on Patterns of Cardiac Stress Testing After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017 , 10, e00457	5.8	6
130	Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial. <i>Circulation</i> , 2019 , 140, 1960-1963	16.7	6
129	Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 45, 225-233	5.1	6
128	Characteristics and evidence-based management of stable coronary artery disease patients in Canada compared with the rest of the world: insights from the CLARIFY registry. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 132-7	3.8	6
127	Efficacy of early invasive management post-fibrinolysis in men versus women with ST-elevation myocardial infarction: a subgroup analysis from Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). <i>American Heart Journal</i> , 2012 , 164, 343-50	4.9	6
126	Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 12-20	7	6
125	Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non-ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2011 , 161, 878-85	4.9	6

124	Pulmonary artery catheterization in patients with acute coronary syndromes. <i>American Heart Journal</i> , 2009 , 158, 170-6	4.9	6
123	Impact of delayed presentation on management and outcome of non-ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2008 , 156, 262-8	4.9	6
122	Clinical implications of a next-day follow-up electrocardiogram in patients with non-ST elevation acute coronary syndromes. <i>American Heart Journal</i> , 2008 , 156, 797-803	4.9	6
121	Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial. <i>American Heart Journal</i> , 2005 , 149, S73-80	4.9	6
120	The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy. <i>American Heart Journal</i> , 2006 , 151, 791-7	4.9	6
119	Short- and long-term outcomes of patients with electrocardiographic left ventricular hypertrophy after fibrinolysis for acute myocardial infarction. <i>American Journal of Cardiology</i> , 2005 , 96, 1050-2	3	6
118	Standards for the function of an academic 12-lead electrocardiographic core laboratory. <i>Journal of Electrocardiology</i> , 2001 , 34, 41-7	1.4	6
117	Acute coronary thrombotic occlusion following exercise testing 6 weeks after percutaneous transluminal coronary angioplasty. <i>Catheterization and Cardiovascular Diagnosis</i> , 1992 , 27, 40-4		6
116	Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. <i>Clinical Cardiology</i> , 2020 , 43, 24-32	3.3	6
115	Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study. <i>American Heart Journal</i> , 2018 , 196, 56-64	4.9	6
114	Marital status and outcomes after myocardial infarction: Observations from the Canadian Observational Antiplatelet Study (COAPT). <i>Clinical Cardiology</i> , 2018 , 41, 285-292	3.3	5
113	Long-term Follow-up of the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). <i>Canadian Journal of Cardiology</i> , 2018 , 34, 736-743	3.8	5
112	Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. <i>American Heart Journal</i> , 2018 , 197, 1-8	4.9	5
111	Efficacy of Early Invasive Management After Fibrinolysis for ST-Segment Elevation Myocardial Infarction in Relation to Initial Troponin Status. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1221.e11-1221.e18	3.8	5
110	Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. <i>American Heart Journal</i> , 2019 , 215, 106-113	4.9	5
109	Stress testing after percutaneous coronary interventions: a population-based study. <i>CMAJ Open</i> , 2017 , 5, E417-E423	2.5	5
108	Has the Clopidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) of early β -blocker use in acute coronary syndromes impacted on clinical practice in Canada? Insights from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2011 , 161, 291-7	4.9	5
107	Use of a treatment optimization algorithm involving statin-ezetimibe combination aids in achievement of guideline-based low-density lipoprotein targets in patients with dyslipidemia at high vascular risk Guideline-based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANCE). <i>Canadian Journal of Cardiology</i> , 2011 , 27, 138-45	3.8	5

106	How many cardiovascular events can be prevented with optimal management of high-risk Canadians?. <i>Canadian Journal of Cardiology</i> , 2008 , 24, 363-8	3.8	5
105	Low-molecular-weight heparins in ischemic heart disease. <i>Current Opinion in Cardiology</i> , 2004 , 19, 309-16.	16.1	5
104	Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial). <i>American Journal of Cardiology</i> , 2000 , 86, 24-9	3	5
103	Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 435-450	15.1	5
102	Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. <i>International Journal of Cardiology</i> , 2016 , 218, 291-297	3.2	5
101	International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing. <i>Pharmacogenetics and Genomics</i> , 2019 , 29, 76-83	1.9	5
100	Short term outcome following acute phase switch among P2Y inhibitors in patients presenting with acute coronary syndrome treated with PCI: A systematic review and meta-analysis including 22,500 patients from 14 studies. <i>IJC Heart and Vasculature</i> , 2019 , 22, 39-45	2.4	5
99	A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 940-942	3.8	4
98	Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. <i>International Journal of Cardiology</i> , 2020 , 311, 7-14	3.2	4
97	Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEYOUTCOMES. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 448-451	15.1	4
96	Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 31-37	3.8	4
95	Routine invasive management early after fibrinolysis: relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7 randomized controlled trials. <i>American Heart Journal</i> , 2014 , 168, 757-65	4.9	4
94	Management of risk factors among ambulatory patients at high cardiovascular risk in Canada: a follow-up study. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 1586-92	3.8	4
93	Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy. <i>CJC Open</i> , 2020 , 2, 118-128	2	4
92	Relation of High Lipoprotein(a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease. <i>Advances in Therapy</i> , 2020 , 37, 4568-4584	4.1	4
91	Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27 979 Patients With Incident Acute Coronary Syndrome. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e006646	5.8	4
90	Duration of dual antiplatelet therapy and associated outcomes following percutaneous coronary intervention for acute myocardial infarction: contemporary practice insights from the Canadian Observational Antiplatelet Study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2017 , 3, 303-311	4.6	4
89	Pulse pressure in acute coronary syndromes: Comparative prognostic significance with systolic blood pressure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 309-317	4.3	4

88	Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial. <i>American Heart Journal</i> , 2021 , 231, 18-24	4.9	4
87	Electrocardiographic Findings in Patients With Acute Coronary Syndrome Presenting With Out-of-Hospital Cardiac Arrest. <i>American Journal of Cardiology</i> , 2018 , 121, 294-300	3	4
86	Short Duration vs Standard Duration of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents - A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials. <i>Journal of Invasive Cardiology</i> , 2016 , 28, E203-E210	0.7	4
85	Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial.. <i>Lancet Diabetes and Endocrinology</i> , 2022 ,	18.1	4
84	Alirocumab after acute coronary syndrome in patients with a history of heart failure.. <i>European Heart Journal</i> , 2021 ,	9.5	4
83	Association Between Patient and Physician Sex and Physician-Estimated Stroke and Bleeding Risks in Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 160-168	3.8	3
82	Efficacy and safety of a routine early invasive strategy in relation to time from symptom onset to fibrinolysis (a subgroup analysis of TRANSFER-AMI). <i>American Journal of Cardiology</i> , 2015 , 115, 1005-12	3	3
81	Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY ACS trial. <i>Coronary Artery Disease</i> , 2018 , 29, 469-476	1.4	3
80	Management and outcomes of non-ST elevation acute coronary syndromes in relation to previous use of antianginal therapies (from the Canadian Global Registry of Acute Coronary Events [GRACE] and Canadian Registry of Acute Coronary Events [CANRACE]). <i>American Journal of Cardiology</i> , 2013 , 112, 51-6	3	3
79	Relation between previous angiotensin-converting enzyme inhibitor use and in-hospital outcomes in acute coronary syndromes. <i>American Journal of Cardiology</i> , 2012 , 109, 332-6	3	3
78	Treatment and outcomes of non-ST elevation acute coronary syndromes in relation to burden of pre-existing vascular disease. <i>International Journal of Cardiology</i> , 2013 , 168, 2720-5	3.2	3
77	ST resolution 1 hour after fibrinolysis for prediction of myocardial infarct size: insights from ASSENT 3. <i>American Journal of Cardiology</i> , 2009 , 103, 154-8	3	3
76	The impact of postrandomization crossover of therapy in acute coronary syndromes care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011 , 4, 211-9	5.8	3
75	Risk factors and outcome of in-hospital ischemic stroke in patients with non-ST elevation acute coronary syndromes. <i>International Journal of Cardiology</i> , 2008 , 129, 233-7	3.2	3
74	Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome. <i>American Heart Journal</i> , 2008 , 156, 177-84	4.9	3
73	Statins and SARS-CoV-2 Infection: Results of a Population-Based Prospective Cohort Study of 469749 Adults From 2 Canadian Provinces. <i>Journal of the American Heart Association</i> , 2021 , 10, e022330 ⁶		3
72	Early invasive coronary angiography and acute ischaemic heart failure outcomes. <i>European Heart Journal</i> , 2021 , 42, 3756-3766	9.5	3
71	The relationship between the proportion of admitted high risk ACS patients and hospital delivery of evidence based care. <i>International Journal of Cardiology</i> , 2016 , 222, 86-92	3.2	3

70	Sex And Prognostic Significance of Self-Reported Frailty in Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From the TRILOGY ACS Trial. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 430-437	3.8	3
69	Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019 , 93, E369-E377	2.7	3
68	Performance of acute coronary syndrome approaches in Brazil: a report from the BRACE (Brazilian Registry in Acute Coronary SyndromEs). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 284-292	4.6	3
67	Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 549-559	3.9	3
66	Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?. <i>Canadian Journal of Cardiology</i> , 2005 , 21, 85-90	3.8	3
65	USE OF HIGH-INTENSITY STATIN THERAPY POST-ACUTE CORONARY SYNDROME IN THE ONGOING ODYSSEY OUTCOMES TRIAL OF ALIROCUMAB, A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MONOCLONAL ANTIBODY, VERSUS PLACEBO: INTERIM BASELINE DATA. <i>Journal of the American College of Cardiology</i> , 2017 , 49, 153	15.1	2
64	GOAL Canada: Physician Education and Support Can Improve Patient Management. <i>CJC Open</i> , 2020 , 2, 49-54	2	2
63	CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 1350-1361	3.8	2
62	Prognostic significance of low QRS voltage on the admission electrocardiogram in acute coronary syndromes. <i>International Journal of Cardiology</i> , 2015 , 201, 493	3.2	2
61	Clinical characteristics and outcomes of acute coronary syndrome patients with left anterior hemiblock. <i>Heart</i> , 2014 , 100, 1456-61	5.1	2
60	Efficacy of an early invasive strategy after fibrinolysis in ST-elevation myocardial infarction relative to the extent of coronary artery disease. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 1555-61	3.8	2
59	Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 34, 114-9	5.1	2
58	Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial. <i>Coronary Artery Disease</i> , 2013 , 24, 321-7	1.4	2
57	Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY). <i>American Journal of Cardiology</i> , 2009 , 104, 1330-5	3	2
56	Non-alcoholic fatty liver disease and outcomes in persons with acute coronary syndromes: insights from the GRACE-ALT analysis. <i>Heart Asia</i> , 2012 , 4, 137-40	1.9	2
55	Comparison of effectiveness of enoxaparin versus unfractionated heparin to reduce silent and clinically apparent acute myocardial infarction in patients presenting with non-ST-segment elevation acute coronary syndrome. <i>American Journal of Cardiology</i> , 2007 , 99, 186-8	3	2
54	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 417-427	15.1	2
53	ABCD-GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial.. <i>Journal of the American Heart Association</i> , 2022 , 11, e024156	6	2

52	Non-vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) Programme. <i>International Journal of Clinical Practice</i> , 2020 , 74, e13625	2.9	2
51	Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. <i>Diabetic Medicine</i> , 2021 , 38, e14552	3.5	2
50	Contemporary use of guideline-based higher potency P2Y12 receptor inhibitor therapy in patients with moderate-to-high risk non-ST-segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross-sectional study. <i>Clinical Cardiology</i> , 2021 , 44, 839-847	3.3	2
49	Drug Adherence and Long-Term Outcomes in Non-Revascularized Patients Following Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2021 , 152, 49-56	3	2
48	Radial versus femoral access for percutaneous coronary intervention in ST-elevation myocardial infarction patients treated with fibrinolysis: Results from the randomized routine early invasive clinical trials. <i>Cardiovascular Revascularization Medicine</i> , 2016 , 17, 295-301	1.6	2
47	Treatment Inertia in Patients With Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , 2021 , 10, e020126	6	2
46	Preventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromes. <i>Canadian Journal of Cardiology</i> , 2002 , 18, 1179-90	3.8	2
45	Comprehensive Quality of Life Outcomes with Invasive versus Conservative Management of Chronic Coronary Disease in ISCHEMIA.. <i>Circulation</i> , 2022 ,	16.7	2
44	Diabetes association with self-reported health, resource utilization, and prognosis post-myocardial infarction. <i>Clinical Cardiology</i> , 2020 , 43, 1352-1361	3.3	1
43	Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 1461-3	15.1	1
42	Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis. <i>American Heart Journal</i> , 2017 , 193, 46-54	4.9	1
41	Response to Letter Regarding Article, Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From PLATO. <i>Circulation</i> , 2012 , 126,	16.7	1
40	Outcome of patients with acute coronary syndromes enrolled in clinical trials. <i>Coronary Artery Disease</i> , 2009 , 20, 473-6	1.4	1
39	Bedtime administration of graded-release diltiazem in patients with inadequate BP control: a tolerability and efficacy study. <i>American Journal of Cardiovascular Drugs</i> , 2006 , 6, 393-400	4	1
38	Coronary angiography in Q-wave versus non-Q-wave acute myocardial infarction. <i>American Journal of Cardiology</i> , 1995 , 76, 429-30	3	1
37	Increasing Prevalence and Incidence of Atherosclerotic Cardiovascular Disease in Adult Patients in Ontario, Canada From 2002 to 2018.. <i>CJC Open</i> , 2022 , 4, 206-213	2	1
36	Cardiac Stress Testing After Coronary Revascularization. <i>American Journal of Cardiology</i> , 2020 , 136, 9-14	3	1
35	Optimizing screening and management of cardiovascular health in prostate cancer: A review. <i>Canadian Urological Association Journal</i> , 2020 , 14, E458-E464	1.2	1

34	Does management of lipid lowering differ between specialists and primary care: Insights from GOAL Canada. <i>International Journal of Clinical Practice</i> , 2021 , 75, e13861	2.9	1
33	Colchicine for Prevention of Atherothrombotic Events in Patients With Coronary Artery Disease: Review and Practical Approach for Clinicians. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 1837-1845	3.8	1
32	The development of Partners for Health's integrated community pathway for postmyocardial infarction patients. <i>Canadian Journal of Cardiology</i> , 2003 , 19, 231-5	3.8	1
31	Enoxaparin and percutaneous coronary intervention: a Canadian perspective. <i>Canadian Journal of Cardiology</i> , 2005 , 21, 501-7	3.8	1
30	Morphine and Clinical Outcomes in Patients with ST segment elevation Myocardial Infarction Treated with Fibrinolytic and Antiplatelet Therapy: Insights from the TREAT Trial.. <i>American Heart Journal</i> , 2022 , 251, 1-1	4.9	1
29	Adjunctive use of anticoagulants at the time of percutaneous coronary intervention in patients with an acute coronary syndrome treated with fondaparinux: a multinational retrospective review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017 , 3, 214-220	6.4	0
28	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. <i>CJC Open</i> , 2020 , 2, 402-415	2	0
27	Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation: Findings From the CONNECT AF+PCI Study.. <i>CJC Open</i> , 2021 , 3, 1419-1427	2	0
26	Use of antithrombotic therapy for secondary prevention in patients with stable atherosclerotic cardiovascular disease: Insights from the COordinated National Network to Engage Cardiologists in the antithrombotic Treatment of patients with CardioVascular Disease (CONNECT-CVD) study. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14597	2.9	0
25	Accuracy of Cardiovascular Trial Outcome Ascertainment and Treatment Effect Estimates from Routine Health Data: A Systematic Review and Meta-Analysis. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e007903	5.8	0
24	Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction.. <i>Advances in Therapy</i> , 2022 , 39, 1832	4.1	0
23	Access Denied? The Unintended Consequences of Pending Drug Pricing Rules.. <i>Current Oncology</i> , 2022 , 29, 2504-2508	2.8	0
22	Prognostic implications of prominent R wave in electrocardiographic leads V1 or V2 in patients with acute coronary syndrome. <i>American Journal of Cardiology</i> , 2014 , 113, 1962-7	3	
21	Does enoxaparin have enough FINESSE to replace unfractionated heparin in primary percutaneous coronary intervention?. <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 213-4	5	
20	Are acute coronary syndromes risk models too complex? reply. <i>European Heart Journal</i> , 2007 , 28, 2176-2177	2.7	
19	Enoxaparin treatment in unstable coronary artery disease: international cost savings. <i>Chest</i> , 2002 , 121, 666-7	5.3	
18	Exertional sudden coronary death was associated with acute plaque rupture in men. <i>Evidence-based Cardiovascular Medicine</i> , 1999 , 3, 61		
17	Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT).. <i>Heart and Vessels</i> , 2022 , 1	2.1	

16	Association of Cardiology Billing Amounts With Health Care Utilization and Clinical Outcomes in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2021 , 10, e020708	6
15	Clinical risk prediction models for the prognosis and management of acute coronary syndromes. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 222-228	4.6
14	An Association Between Cardiologist Billing Patterns, Health Care Use, and Outcomes in Cardiac Patients. <i>CJC Open</i> , 2021 , 3, 758-768	2
13	Provision of a DAPT Score to Cardiologists and Extension of Dual Antiplatelet Therapy Beyond 1 Year After ACS: Randomized Substudy of the Prospective Canadian ACS Reflective II Study.. <i>CJC Open</i> , 2021 , 3, 1463-1470	2
12	Prevalence of Cardiovascular Disease in a Population-Based Cohort of High-Cost Healthcare Services Users.. <i>CJC Open</i> , 2022 , 4, 180-188	2
11	Cardiovascular risk factor management in patients with diabetes: Does management differ with disease duration?. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107997	3.2
10	Factors associated with actively working in the very long-term following acute coronary syndrome. <i>Clinics</i> , 2021 , 76, e2553	2.3
9	An early invasive strategy reduced the incidence of major cardiac events in patients with unstable coronary syndromes. <i>ACP Journal Club</i> , 2002 , 136, 4	
8	Review: oral glycoprotein IIb/IIIa inhibitors increase mortality and myocardial infarction. <i>ACP Journal Club</i> , 2002 , 137, 85	
7	Objective risk assessment vs standard care for acute coronary syndromes-The Australian GRACE Risk tool Implementation Study (AGRIS): a process evaluation.. <i>BMC Health Services Research</i> , 2022 , 22, 380	2.9
6	Associated Factors and Clinical Outcomes in Mechanical Circulatory Support use in Patients Undergoing High Risk On-Pump Cardiac Surgery: Insights from the LEVO-CTS trial.. <i>American Heart Journal</i> , 2022 , 248, 35-35	4.9
5	Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. <i>Journal of the American Heart Association</i> , 2021 , e023143	6
4	Women with acute myocardial infarction had worse prognosis than men. <i>ACP Journal Club</i> , 1996 , 125, 43	
3	Women had a worse prognosis than men after myocardial infarction. <i>ACP Journal Club</i> , 1999 , 130, 46	
2	Abciximab and heparin given during coronary interventions reduced combined death, MI, and urgent revascularization. <i>ACP Journal Club</i> , 1999 , 131, 40	
1	Review: Oral glycoprotein IIb/IIIa inhibitors increase mortality and myocardial infarction. <i>ACP Journal Club</i> , 2002 , 137, 85	